CA2707858A1 - Treatment of post-traumatic stress disorder - Google Patents

Treatment of post-traumatic stress disorder Download PDF

Info

Publication number
CA2707858A1
CA2707858A1 CA2707858A CA2707858A CA2707858A1 CA 2707858 A1 CA2707858 A1 CA 2707858A1 CA 2707858 A CA2707858 A CA 2707858A CA 2707858 A CA2707858 A CA 2707858A CA 2707858 A1 CA2707858 A1 CA 2707858A1
Authority
CA
Canada
Prior art keywords
nepicastat
post
patient
dopamine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2707858A
Other languages
English (en)
French (fr)
Inventor
Tom Woiwode
Mark Moran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2707858A1 publication Critical patent/CA2707858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2707858A 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder Abandoned CA2707858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
US60/935,036 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
CA2707858A1 true CA2707858A1 (en) 2009-01-29

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2707858A Abandoned CA2707858A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Country Status (12)

Country Link
US (1) US20090054403A1 (cg-RX-API-DMAC7.html)
EP (1) EP2182952A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010534676A (cg-RX-API-DMAC7.html)
CN (1) CN101951912A (cg-RX-API-DMAC7.html)
AU (1) AU2008279091A1 (cg-RX-API-DMAC7.html)
CA (1) CA2707858A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260078A2 (cg-RX-API-DMAC7.html)
MX (1) MX2010000937A (cg-RX-API-DMAC7.html)
NZ (1) NZ583193A (cg-RX-API-DMAC7.html)
RU (1) RU2458691C2 (cg-RX-API-DMAC7.html)
SG (1) SG183069A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009015248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
RU2491067C2 (ru) * 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
US10588890B2 (en) * 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
AU2018204843B2 (en) * 2017-07-05 2023-07-27 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
JP7618230B2 (ja) * 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤
CN120882371A (zh) * 2022-11-30 2025-10-31 闪烁实验室有限公司 使用眼睑跟踪的精神药理学系统和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CN101257907A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
US20100105748A1 (en) * 2007-03-16 2010-04-29 David Weinshenker Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Also Published As

Publication number Publication date
JP2010534676A (ja) 2010-11-11
WO2009015248A1 (en) 2009-01-29
AU2008279091A1 (en) 2009-01-29
US20090054403A1 (en) 2009-02-26
MX2010000937A (es) 2010-06-25
RU2010106014A (ru) 2011-08-27
EP2182952A1 (en) 2010-05-12
RU2458691C2 (ru) 2012-08-20
EP2182952A4 (en) 2010-09-08
CN101951912A (zh) 2011-01-19
SG183069A1 (en) 2012-08-30
NZ583193A (en) 2012-05-25
CO6260078A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
US20090054403A1 (en) Treatment of Post-Traumatic Stress Disorder
US20200383951A1 (en) Methods for treating dependence
Burnette et al. Novel agents for the pharmacological treatment of alcohol use disorder
WO2010124089A2 (en) Methods for treating dependence
Chiou et al. 9-hydroxycanthin-6-one induces penile erection and delays ejaculation
AU2018203524B2 (en) Methods for treating dependence
US20240197756A1 (en) Methods of treatment with neuroactive steroids
EP3897578B1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
AU2014202047A1 (en) Methods for treating dependence
HK1155063A (en) Treatment of post-traumatic stress disorder
HK1241721A1 (en) Methods for treating dependence
HK1143038A (en) Methods for treating dependence
US20210275512A1 (en) Pridopidine for treating drug induced dyskinesias
HK40063144A (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
HK40063144B (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
STEINHEYER et al. Basic and Clinical Aspects of Depression

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140313